The T2238C variant of the atrial natriuretic peptide (ANP) gene has emerged as a novel risk factor for the incidence of cardiovascular events. However, the impact of this variant on cardiovascular outcome in patients with atrial fibrillation (AF) is unknown.
Pastori, D., Carnevale, R., Stanzione, R., Nocella, C., Cotugno, M., Marchitti, S., et al. (2020). T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. INTERNATIONAL JOURNAL OF CARDIOLOGY [10.1016/j.ijcard.2020.08.077].
T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort
Versaci, FrancescoSupervision
;
2020-08-28
Abstract
The T2238C variant of the atrial natriuretic peptide (ANP) gene has emerged as a novel risk factor for the incidence of cardiovascular events. However, the impact of this variant on cardiovascular outcome in patients with atrial fibrillation (AF) is unknown.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
pastori T2238T atrial natriuretic.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
639.06 kB
Formato
Adobe PDF
|
639.06 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
